CDT Equity Inc.

CDT Equity Inc. is a clinical-stage biopharmaceutical company headquartered in Naples, Florida, focused on developing pharmaceutical treatments for autoimmune diseases and idiopathic male infertility. The company's pipeline includes two Phase I-stage candidates: AZD1656, which is being evaluated across multiple indications including type 2 diabetes, renal transplant rejection, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, designed to address idiopathic male infertility. The company was incorporated in Delaware and is listed on Nasdaq.

The company has established a strategic services agreement with Agility Life Sciences, a formulation development contract development and manufacturing organization, to support the development of new solid oral-dosage form products. This partnership provides development capabilities without requiring significant internal infrastructure expansion. CDT Equity operates with a small team of six full-time employees and maintains minimal revenue generation at its current clinical-stage development phase. The company was formerly known as Conduit Pharmaceuticals Inc. until rebranding to CDT Equity Inc. in August 2025. Geographically, operations are concentrated in the United States, with the company's primary presence in Florida.